Patents by Inventor Kim Ellen SCHWENDT
Kim Ellen SCHWENDT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220249654Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).Type: ApplicationFiled: February 7, 2022Publication date: August 11, 2022Applicant: CureVac AGInventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
-
Publication number: 20220211841Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).Type: ApplicationFiled: February 7, 2022Publication date: July 7, 2022Applicant: CureVac AGInventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
-
Publication number: 20220211838Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP).Type: ApplicationFiled: February 7, 2022Publication date: July 7, 2022Applicant: CureVac AGInventors: Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
-
Publication number: 20220040281Abstract: The present invention is directed to a coding RNA for a Malaria vaccine. The coding RNA comprises at least one heterologous untranslated region (UTR), preferably a 3?-UTR and/or a 5?-UTR, and a coding region encoding at least one antigenic peptide or protein derived from a Malaria parasite, in particular at least one antigenic protein derived from circumsporozoite protein (CSP) of a Malaria parasite (e.g. Plasmodium falciparum). The present invention is also directed to compositions and vaccines comprising said coding RNA in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). Further, the invention concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The invention is also directed to a method of treating or preventing Malaria, and the first and second medical uses of the coding RNA, the composition, the vaccine, and the kit.Type: ApplicationFiled: December 20, 2019Publication date: February 10, 2022Applicant: CureVac AGInventors: Kim Ellen SCHWENDT, Benjamin PETSCH, Nicole ROTH
-
Publication number: 20210401966Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.Type: ApplicationFiled: September 8, 2021Publication date: December 30, 2021Applicant: CureVac AGInventors: Susanne RAUCH, Kim Ellen SCHWENDT, Benjamin PETSCH
-
Patent number: 11141474Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.Type: GrantFiled: May 4, 2017Date of Patent: October 12, 2021Assignee: CureVac AGInventors: Susanne Rauch, Kim Ellen Schwendt, Benjamin Petsch
-
Publication number: 20210162037Abstract: The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.Type: ApplicationFiled: May 4, 2017Publication date: June 3, 2021Inventors: Edith JASNY, Susanne RAUCH, Kim Ellen SCHWENDT, Benjamin PETSCH, Karen SLOBOD
-
Publication number: 20200163878Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.Type: ApplicationFiled: October 26, 2017Publication date: May 28, 2020Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT, Ying TAM